

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Cornell University Weill Medical College Human Immune Monitoring Core Facility

RRID:SCR_021669

Type: Tool

Proper Citation

Cornell University Weill Medical College Human Immune Monitoring Core Facility
(RRID:SCR_021669)

Resource Information

URL:

https://wcmc.corefacilities.org/service_center/show_external/5753/human_immune_monitoring_core

Proper Citation: Cornell University Weill Medical College Human Immune Monitoring Core Facility (RRID:SCR_021669)

Description: Core provides technology platforms and services for single cell, in situ, and multiomic analysis for cutting edge immunology research and clinical studies to help make impactful discoveries and develop improved treatments for human diseases. Services include Spectral flow cytometry (Cytek Aurora), Imaging mass cytometry (Fluidigm Hyperion), CyTOF mass cytometry (Fluidigm Helios).

Abbreviations: HIMC

Synonyms: WCM Human Immune Monitoring Core (HIMC) at Weill Cornell Medicine

Resource Type: access service resource, service resource, core facility

Keywords: USEDit, ABRF, immunology, Spectral flow cytometry, Cytek Aurora, Imaging mass cytometry, Fluidigm Hyperion, CyTOF mass cytometry, Fluidigm Helios

Resource Name: Cornell University Weill Medical College Human Immune Monitoring Core Facility

Resource ID: SCR_021669

Alternate IDs: ABRF_1203

Alternate URLs: <https://coremarketplace.org/?FacilityID=1203>

Record Creation Time: 20220129T080356+0000

Ratings and Alerts

No rating or validation information has been found for Cornell University Weill Medical College Human Immune Monitoring Core Facility.

No alerts have been found for Cornell University Weill Medical College Human Immune Monitoring Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gonzalez-Kozlova E, et al. (2024) Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. Cancer research communications, 4(7), 1726.